| Autor: |
Dahl K; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Raun K; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hansen JL; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Poulsen C; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., de la Cour CD; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Clausen TR; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hansen AMK; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., John LM; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark.; Novo Nordisk China, Novo Nordisk Research Center China, Building 2, 20 Life Science Park Road, Changping District, 102206 Beijing, China., Plesner A; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Sun G; Novo Nordisk China, Novo Nordisk Research Center China, Building 2, 20 Life Science Park Road, Changping District, 102206 Beijing, China., Schlein M; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Skyggebjerg RB; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Kruse T; Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark. |
| Abstrakt: |
Amylin, a member of the calcitonin family, acts via amylin receptors in the hindbrain and hypothalamus to suppress appetite. Native ligands of these receptors are peptides with short half-lives. Conjugating fatty acids to these peptides can increase their half-lives. The long-acting human amylin analog, NN1213, was generated from structure-activity efforts optimizing solubility, stability, receptor affinity, and selectivity, as well as in vivo potency and clearance. In both rats and dogs, a single dose of NN1213 reduced appetite in a dose-dependent manner and with a long duration of action. Consistent with the effect on appetite, studies in obese rats demonstrated that daily NN1213 dosing resulted in a dose-dependent reduction in body weight over a 21-day period. Magnetic resonance imaging indicated that this was primarily driven by loss of fat mass. Based on these data, NN1213 could be considered an attractive option for weight management in the clinical setting. |
